Eli Lilly (Lly) win Q1 2025
The Eli Lilly & Co. logo in the Digital Health Innovation Hub facility of the company in Singapore, on Thursday, November 14, 2024.
Erz huiying | Bloomberg | Getty pictures
Eli Lilly On Thursday, sales and profits reported in the first quarter, which were estimated as a demand for weight loss and diabetes medication, but reduced their profit guidelines of the entire year due to charges in connection with a recently carried out cancer treatment contract.
The pharmaceutical now assumes that its adjusted result for the 2025 financial year is between $ 20.78 and $ 22.28 per share from USD $ 24 per share.
Eli Lilly kept his sales advice of 58 billion US dollars up to $ 61 billion.
The following reported Eli Lilly in the first quarter compared to what Wall Street expected, based on a survey of LSEG analysts:
- Win each share: $ 3.34 adapted compared to USD 3.02
- Revenue: 12.73 billion US dollars expected compared to $ 12.67 billion
This story develops. Please check for updates.
